Insulet Co. (NASDAQ:PODD) Given Average Rating of “Moderate Buy” by Analysts

Insulet Co. (NASDAQ:PODD) has earned an average rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $234.60.

PODD has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Citigroup lifted their target price on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler lifted their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Barclays lifted their target price on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Finally, BTIG Research dropped their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sunbelt Securities Inc. purchased a new stake in Insulet in the first quarter worth about $29,000. International Assets Investment Management LLC purchased a new stake in Insulet in the second quarter worth about $32,000. UMB Bank n.a. lifted its holdings in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the period. Jones Financial Companies Lllp purchased a new stake in Insulet in the fourth quarter worth about $40,000. Finally, CVA Family Office LLC lifted its holdings in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Insulet Price Performance

PODD stock opened at $233.10 on Friday. The firm has a 50 day moving average of $214.20 and a 200-day moving average of $194.64. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. Insulet has a 12 month low of $125.82 and a 12 month high of $243.98. The firm has a market capitalization of $16.34 billion, a P/E ratio of 42.38, a price-to-earnings-growth ratio of 4.34 and a beta of 1.21.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same quarter last year, the business posted $0.38 earnings per share. Insulet’s revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts predict that Insulet will post 3.04 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.